Overview

Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness

Status:
Recruiting
Trial end date:
2021-11-15
Target enrollment:
Participant gender:
Summary
This is a Phase 2b, multi-center, double-blind, randomized, placebo-controlled, parallel-group study of NKT versus placebo in otherwise healthy adults presenting with acute uncomplicated ILI due to influenza or other respiratory viruses in a community setting.
Phase:
Phase 2
Details
Lead Sponsor:
Emergo Therapeutics, Inc.